Correlation between oral microbial homeostasis and cisplatin sensitivity in patients with oral squamous cell carcinoma

doi:10.19438/j.cjoms.2021.06.004

Abstract

Abstract: PURPOSE: To explore the correlation between oral microbial homeostasis and cisplatin sensitivity in patients with oral squamous cell carcinoma(OSCC). METHODS: Saliva samples were collected from 29 OSCC patients before chemotherapy, according to RECIST 1.1 evaluation criteria, the recruited patients were sorted into two groups: cisplatin resistant group (ineffective) and cisplatin sensitive group (effective). 16S rRNA gene sequencing was used to analyze the species composition, community diversity, abundance of oral microorganisms and comparison between samples. The data were analyzed with SPSS 19.0 software package, and LEfSe was used to analyze the species difference between the two groups. RESULTS: Compared with cisplatin chemotherapy-sensitive group, the microbial diversity in saliva samples of the cisplatin resistant group increased significantly. At genus level, Atopobium, Coriobacteriaceae, Parvimonas, Eubacterium yurii and Fusobacteriumin in the chemotherapy-resistant group were significantly increased compared with the sensitive group. CONCLUSIONS: There is significant difference in the structure and composition of oral microorganisms between cisplatin resistant group and cisplatin sensitive group, suggesting that microbes may become biomarkers before chemotherapy for patients with OSCC.

Key words: Oral microorganism, Oral squamous cell carcinoma, Cisplatin resistance, 16SrRNA, Biomarkers

CLC Number:

R739.8

HUANG Jin-yun, ZHANG Xin-yi, JU Hou-yu, JI Hong-hai, REN Guo-xin. Correlation between oral microbial homeostasis and cisplatin sensitivity in patients with oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(6): 500-505.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Kademani D.Oral cancer[J]. Mayo Clin Proc, 2007, 82(7): 878-887.
[3] Petersen PE.The World Oral Health Report 2003: continuous improvement of oral health in the 21st century-the approach of WHO Global Oral Programmer[J]. Community Dent Oral Epidemiol, 2003, 31(Suppl 1): 3-23.
[4] Spoerl S, Gerken M, Mamilos A, et al.Lymph node ratio as a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study[J]. Clin Oral Investig, 2021, 25(4):1705-1713.
[5] Pfister DG, Spencer S, Brizel DM, et al.Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2014, 12(10): 1454-1487.
[6] Cheraghlou S, Schettino A, Zogg CK, et al.Changing prognosis of oral cancer: an analysis of survival and treatment between 1973 and 2014[J]. Laryngoscope, 2018, 128(12): 2762-2769.
[7] Whitmore SE, Lamont RJ.Oral bacteria and cancer[J]. PLoS Pathog, 2014, 10(3): 981-984.
[8] 尚伟, 郑家伟. 口腔及口咽癌新版TNM分期与NCCN诊治指南部分解读[J]. 中国口腔颌面外科杂志, 2018, 16(6): 533-546.
[9] Krajewski KM, Nishino M, Ramaiya NH et al. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy[J]. AJR Am J Roentgenol, 2015, 204(3): 282-288.
[10] Taur Y, Jenqr R, Perales M, et al.The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation[J]. Blood,2014, 124(7): 1174-1182.
[11] Pope J, Tomkovich S, Yang Y, et al.Microbiota as a mediator of cancer progression and therapy[J]. Transl Res, 2017, 179: 139-154.
[12] Iida N, Dzutsev A, Stewart CA, et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013, 342( 6161): 967-970.
[13] Brahe LK, Le Chatelier E, Prifti E, et al.Specific gut microbiota features and metabolic markers in postmenopausal women with obesity[J]. Nutr Diabetes, 2015, 5(6): e159-e162.
[14] Pushalkar S, Mane S, Ji X, et al.Microbial diversity in saliva of oral squamous cell carcinoma[J]. FEMS Immunol Med Microbiol, 2011, 61(3): 269-277.
[15] Schmidt BL, Kuczynski J, Bhattacharya A, et al.Changes in abundance of oral microbiota associated with oral cancer[J]. PLoS One, 2014, 9(6): e98741-e98743.
[16] Al-Hebshi N, Nasher AT, Idris AM, et al.Robust species taxonomy assignment algorithm for 16S rRNA NGS reads: application to oral carcinoma samples[J]. J Oral Microbiol, 2015, 7: 28934-28938.
[17] Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, et al.16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment[J]. Oncotarget, 2016, 7(32): 51320-51334.
[18] Sun DL, Jiang X, Wu Q, et al.Intragenomic heterogeneity of 16S rRNA genes causes overestimation of prokaryotic diversity[J]. Appl Environ Microbiol, 2013, 79(19): 5962-5969.
[19] Wang H, Funchain P, Bebek G, et al.Microbiomtic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas[J]. Genome Med, 2017, 9(1): 14-18.
[20] Pushalkar S, Ji X, Li Y, et al.Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma[J]. BMC Microbiol, 2012, 12: 144-146.
[21] Hu X, Zhang Q, Hua H, et al.Changes in the salivary microbiota of oral leukoplakia and oral cancer[J]. Oral Oncol, 2016, 56: e6-e8.
[22] Yu TC, Guo F, Yu Y, et al.Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3) : 548-563.